Clinical Trial Update: Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for trilaciclib in early-stage triple-negative breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple Negative Breast Cancer

Drugs mentioned

• trilaciclib (trilaciclib)

Snippet

Sponsor: G1 Therapeutics, Inc. | Conditions: Triple Negative Breast Cancer, Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-03-12